ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM Immupharma Plc

2.22
0.045 (2.07%)
Last Updated: 09:03:56
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.045 2.07% 2.22 2.10 2.22 2.22 2.22 2.22 228,080 09:03:56
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.90 7.23M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.18p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 3.78p.

Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £7.23 million. Immupharma has a price to earnings ratio (PE ratio) of -1.90.

Immupharma Share Discussion Threads

Showing 8501 to 8519 of 39125 messages
Chat Pages: Latest  341  340  339  338  337  336  335  334  333  332  331  330  Older
DateSubjectAuthorDiscuss
03/1/2018
09:06
Dontshout,

Work backwards from those numbers; Taking the higher of the two, £100 a share with current share price (for ease at £2 and mkt cap £250mln)

so £100 = £12.5bln

Can/could such a valuation be justified or arrived at using p/e multiples with the sales potential alluded to by the BOD here?

sportbilly1976
03/1/2018
09:03
Will everyone please check their local village, I think one out there is missing an idiot.
hamhamham1
03/1/2018
09:02
I know it seems too good to be true but is it really so airy to imagine a company that has such a strong potential as Immupharma’s offering of halting or giving leads to - may I dare to wish,- starting cures, with its patented P140 etcetera etcetera, at least 7 major world-wide diseases, each of which affects many millions of people, to be worth at least seven times what it may sell Lupuzor for? Modern medicine is now making amazing breakthroughs every month. Why couldn't this one be one of the great breakthroughs? Its record thus far is heart-warming to say the least. I have decades of experience in winning and losing a lot, and it may sound ridiculous and I don't want to sound madly optimistic, but is £80 or £100 per share really too far out of the question?
dontshoutatonce
03/1/2018
08:54
Sounds ghastly
longshanks
03/1/2018
08:53
great thanks
qs99
03/1/2018
08:48
hamhamham Do you think you are safe to make comments like that just because I said I was going when njb67 was gone? Well you are not. Good - I am delighted I have upset you again. It is a pity that he has left you, his ponderous, sycophant wingman and angry young lady zho behind. If you bothered to properly read posts you would know my price prediction is far far less then £100
runtoma
03/1/2018
08:37
Last evaluation is 28 days after last dose, which was announced on 21/12/2017, so last dose might have been the day before to which you then add 28 days.
hottingup
03/1/2018
08:31
They released the RNS on the 21st, if you add 28 days ( which was their dosing regimen which they said its fixed ) we should expect an RNS on the 18th, which is a thursday
immy1992
03/1/2018
08:20
Someone mentioned the 17th Jan didn't they? DYOR etc....would be useful to know the exact day, anyone know? thanks
qs99
03/1/2018
08:08
The Phase 3 can be unblinded in around two weeks from now and we could see it break through the £40 level if the results beat Benlysta.
englishlongbow
03/1/2018
07:44
IMM have two platforms. Gilhead just paid over $11 billion to get Kite's platform.
money maker1
03/1/2018
07:24
If Imm have a drug that can generate multi billion pound sales the value of the company is a multiple of those sales, and even more if they have an entire platform applicable to multiple diseases.
stealth wealth
03/1/2018
07:04
Runt. When will you learn that just because anyone (eg njb67) doesn't think the share is going to hit £100, that isn't negativity, in fact some may say it's objectivity.
You are by far the most annoying poster on here.

hamhamham1
03/1/2018
02:21
Just having breakfast by the pool, 27c clear, nice breeze, hope it’s not too cold in blighty.

By the time trading starts in paradise i’m Expecting a record number of green thumbs up 😁

ny boy
03/1/2018
01:54
The Finn cap 237p valuation is based on pre fda approval etc as far as I am aware.

Just a guide, no one knows how high we can go here, it’s partly the fear of losing out and less stock available as investors buy to generally hold. Any future tree shakes can provide useful top up opportunities. GLA

ny boy
02/1/2018
23:16
The more logical comparisons are with other pharma companies like HGSi and Kite Pharma, whose market caputalisations went ballstic.
top tips
02/1/2018
23:04
GKP... grrrrr
reptile3
02/1/2018
22:54
Some of the valuations quoted here remind me of the glory days of GKP. It was going to make thousands of millionaires overnight, just look at what happened and how many disappointed investors were left to lick their wounds. I don't have a figure for what IMM will be worth if it gets full approvals, all I know it will be a bigger number than now, that's why I am a long term holder
ayl30
02/1/2018
21:59
He will be back under a new alias, probably already operating in a different one anyway. This much is guaranteed judging by his reactive posts. We are not naieve here are we folks?
andyr42
Chat Pages: Latest  341  340  339  338  337  336  335  334  333  332  331  330  Older

Your Recent History

Delayed Upgrade Clock